To replicate and extend findings suggesting that higher serum alpha-linolenic acid (ALA) levels are associated with reduced disease activity and progression in multiple sclerosis (MS), specifically focusing on clinical and MRI outcomes.
Key Findings:
Higher serum ALA levels predicted lower EDSS scores (β = −0.41, p < 0.05) and larger brain volume (β = 0.22, p < 0.05).
ALA measures showed high reliability over time (κ = 0.83).
ALA was not a significant mediator of brain volume or lesion effects on EDSS.
No long-term predictive value of ALA on clinical or cognitive changes was found.
Interpretation:
The study replicates previous findings linking higher serum ALA levels with reduced disability and increased brain volume in MS, but does not support ALA's role in long-term disease progression, suggesting a need for further research.
Limitations:
The sample size was limited to 85 participants, which may affect the generalizability of the findings.
Longitudinal predictive analyses did not show significant associations with long-term outcomes.
Conclusion:
While higher serum ALA levels are associated with reduced disability and increased brain volume in MS, their prognostic value for long-term progression remains unclear, highlighting the need for further investigation.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
